Shenzhen Geno-immune Medical Institute

This early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…

This early-phase trial tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if it is safe and can control the disease as a first treatment. About 20 participants will…

This early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…

This early-phase trial tests a combination of CAR T cells that target different markers on leukemia cells in patients with relapsed or hard-to-treat acute myeloid leukemia (AML). The goal is to see if this approach is safe and can shrink or eliminate the cancer. Up to 10 particip…

This study tests a new treatment for a rare and aggressive brain cancer called diffuse midline glioma (including DIPG). The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a specific marker (H3K27M). The trial a…

This trial tests a gene therapy for X-linked adrenoleukodystrophy (X-ALD), a rare genetic disease that damages the brain. The therapy uses a modified virus to deliver a working gene into the body via spinal fluid and veins. About 30 patients aged 1 year and older will be enrolled…

This study tests a new treatment for advanced ovarian cancer using a patient's own immune cells, which are modified in a lab to better attack the cancer. About 100 women with stage III or IV ovarian cancer will receive these modified cells to see if they are safe and can shrink t…

This study tests a new treatment called 4SCAR19 cells for people with B-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The trial aims to check safety…

This early-stage study tests a gene therapy for hemophilia B, a bleeding disorder. Ten male participants (age 2 and up) will receive their own stem cells modified with a lentiviral vector to produce clotting factor IX. The goal is to see if the treatment is safe and can reduce bl…

This study tests a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. It uses a mix of specially designed immune cells (CAR-T cells) that target up to seven different markers on cancer cells. The goal is to see if this com…

This early-stage study tests a gene therapy for hemophilia A, a bleeding disorder. The treatment uses a modified virus to deliver a working gene into the patient's own stem cells, aiming to help the body produce the missing clotting factor VIII. Ten male participants aged 2 and o…

This study tests a new type of CART immunotherapy for people with B-cell acute lymphoblastic leukemia (ALL) whose cancer cells do not have the CD19 marker, either from the start or after previous CD19-targeted CART therapy. The treatment uses a patient's own immune cells, modifie…

This study tests a new treatment for gastrointestinal cancers using a patient's own immune cells, which are engineered in a lab to better recognize and attack cancer. The goal is to see if this approach is safe and can shrink tumors. About 100 adults with certain cancer markers a…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. It is for people whose cancer has not responded to standard therapy. The goal is to see if this cell therapy is safe and can shri…

This trial tests a new gene therapy for Chronic Granulomatous Disease (CGD), a rare immune disorder that leaves patients vulnerable to severe infections. The therapy uses a modified virus to deliver a working copy of the faulty gene into the patient's own blood stem cells. The go…

This study tests a new treatment called 4sCAR-DLL3 CAR-T therapy for people with certain brain tumors, including glioblastoma and DIPG. The therapy uses a patient's own immune cells that are modified in a lab to target a protein called DLL3 found on tumor cells. The goal is to se…

This trial tests a gene therapy for X-linked severe combined immunodeficiency (SCID-X1), also known as bubble boy disease. It involves a single IV injection of a modified virus to correct the faulty gene. The study aims to restore immune function and reduce infections in 10 patie…

This early-stage trial tests a personalized vaccine made from a patient's own immune cells (dendritic cells) to keep multiple myeloma or plasmacytoma in remission. The study includes 10 patients who have already achieved very good partial or complete remission after other treatme…

This early-stage study tests a new stem cell therapy made from fetal cells for people with type 2 diabetes. The goal is to see if it is safe and can help improve blood sugar control. About 30 adults with poorly controlled diabetes will receive the treatment and be monitored for s…

This study tests a new treatment using a patient's own immune cells, which are engineered in a lab to better recognize and attack cancer. The goal is to see if these cells are safe and can shrink tumors. The trial involves 100 people with different types of cancer whose tumors ha…

This early-phase study tests a new type of universal CAR-T cell therapy for people with multiple myeloma that is in remission but hard to treat. The goal is to see if these cells are safe and can control the disease. About 20 participants will receive the treatment and be monitor…

This study tests a new combination of immune cells—CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines—to fight advanced melanoma that has spread or come back after standard treatment. About 30 adults aged 18 to 75 with confirmed melanoma antigens will r…

This study tests a new treatment called multi-CAR T cell therapy for people with acute myeloid leukemia (AML) that has come back or not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to target multiple markers on leukemia cells. The g…

This study tests a new treatment for people with advanced melanoma that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, NG2 and DLL3, found on melanoma cells. The goal is to see if th…

This early-stage trial tests a new cell therapy called 4SCAR-T for people with advanced bladder cancer that has spread and has no standard treatments left. About 20 participants will receive specially engineered immune cells designed to attack the cancer. The goal is to see if th…

This early-stage trial tests a one-time intravenous gene therapy for ADA-SCID, a life-threatening genetic disorder that leaves babies without a working immune system. The treatment uses a harmless virus to deliver a corrected gene directly into the patient's blood, aiming to rest…

This early-stage trial tests a special type of stem cell (cfMSC) given by IV to 30 adults aged 40-80 with moderate to severe COPD whose symptoms are not well-controlled by standard medicines. The main goals are to check safety and see if the treatment can improve lung function. T…